Zomedica Corp.
ZOM was delisted on the 4th of March, 2025.
9 hedge funds and large institutions have $689K invested in Zomedica Corp. in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$432K |
| 2 |
Millennium Management
New York
|
+$136K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$58K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$8.58K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$4.44K |
Top Sellers
ZOM Hedge Fund Activity: Q4 2017 in Review
9 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Zomedica Corp. (ZOM) for Q4 2017, worth a combined $689K.
Buyers outnumbered sellers: 9 funds opened new ZOM positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $432K.
- 9 institutional investors held Zomedica Corp. (ZOM) as of Q4 2017, up from 0 in Q3 2017.
- Funds reported $689K of Zomedica Corp. stock for Q4 2017.
- 9 funds opened new Zomedica Corp. positions in Q4 2017 and 0 closed out, a net change of +9 holders.
- The largest Zomedica Corp. buyer in Q4 2017 was Cambridge Investment Research Advisors, an estimated $432K added.
Based on aggregated 13F filings for Q4 2017.